Literature DB >> 32081407

Pharmacogenomics in pregnancy.

Hannah K Betcher1, Alfred L George2.   

Abstract

Pregnant women frequently take prescription and over the counter medications. The efficacy of medications is affected by the many physiological changes during pregnancy, and these events may be further impacted by genetic factors. Research on pharmacogenomic and pharmacokinetic influences on drug disposition during pregnancy has lagged behind other fields. Clinical investigators have demonstrated altered activity of several drug metabolizing enzymes during pregnancy. Emerging evidence also supports the influence of pharmacogenomic variability in drug response for many important classes of drugs commonly used in pregnancy. Prescribing medications during pregnancy requires an understanding of the substantial dynamic physiologic and metabolic changes that occur during gestation. Pharmacogenomics also contributes to the inter-individual variability in response to many medications, and more research is needed to understand how best to manage drug therapy in pregnant women.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug metabolism; Drug therapy; Pharmacogenetics; Pharmacogenomics; Pregnancy

Year:  2020        PMID: 32081407      PMCID: PMC7214196          DOI: 10.1016/j.semperi.2020.151222

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  52 in total

Review 1.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Authors:  J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2015-06-29       Impact factor: 6.875

3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

4.  PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Authors:  James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-11       Impact factor: 3.908

5.  Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.

Authors:  Arne Reimers; Grethe Helde; Eylert Brodtkorb
Journal:  Epilepsia       Date:  2005-09       Impact factor: 5.864

6.  Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Authors:  Dorothy K Sit; James M Perel; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

Review 7.  Guidelines for maternal codeine use during breastfeeding.

Authors:  Parvaz Madadi; Myla Moretti; Nada Djokanovic; Pina Bozzo; Irena Nulman; Shinya Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-11       Impact factor: 3.275

8.  Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Authors:  J M Pulley; J C Denny; J F Peterson; G R Bernard; C L Vnencak-Jones; A H Ramirez; J T Delaney; E Bowton; K Brothers; K Johnson; D C Crawford; J Schildcrout; D R Masys; H H Dilks; R A Wilke; E W Clayton; E Shultz; M Laposata; J McPherson; J N Jirjis; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

9.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.

Authors:  R McGready; K Stepniewska; E Seaton; T Cho; D Cho; A Ginsberg; M D Edstein; E Ashley; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

10.  MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION.

Authors:  Akshanth R Polepally; Page B Pennell; Richard C Brundage; Zachary N Stowe; D Jeffrey Newport; Adele C Viguera; James C Ritchie; Angela K Birnbaum
Journal:  Ann Clin Transl Neurol       Date:  2014-02       Impact factor: 4.511

View more
  3 in total

Review 1.  An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics.

Authors:  Ahizechukwu C Eke
Journal:  J Basic Clin Physiol Pharmacol       Date:  2021-12-08

2.  Does the Fetus Limit Antibiotic Treatment in Pregnant Patients with COVID-19?

Authors:  Tito Ramírez-Lozada; María Concepción Loranca-García; Claudia Erika Fuentes-Venado; Carmen Rodríguez-Cerdeira; Esther Ocharan-Hernández; Marvin A Soriano-Ursúa; Eunice D Farfán-García; Edwin Chávez-Gutiérrez; Xóchitl Ramírez-Magaña; Maura Robledo-Cayetano; Marco A Loza-Mejía; Ivonne Areli Garcia Santa-Olalla; Oscar Uriel Torres-Paez; Rodolfo Pinto-Almazán; Erick Martínez-Herrera
Journal:  Antibiotics (Basel)       Date:  2022-02-16

3.  Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.

Authors:  Ethan A Poweleit; Margaret A Cinibulk; Sarah A Novotny; Melissa Wagner-Schuman; Laura B Ramsey; Jeffrey R Strawn
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.